Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TENX

Tenax Therapeutics Inc

1.37

Aug 10 • 1:40 PM ET -12.07 (-89.83%)

Healthcare Biotechnology USA Micro NASD

Today, 7:10 AMTenax Therapeutics' Phase 3 LEVEL trial of TNX-103 in PH-HFpEF fails primary and key secondary endpoints

Peers: OABI CAMP HUMA RNA TNXP UNCY WHWK MIST CNTX KPTI

| Held by: VTI IWM VXF IWN VTWO IWC DFAS VFMO FESM DFMC

Scroll to Statements

Index	RUT
Market Cap	51.15M
Enterprise Value	-66.83M
Income	-64.86M
Sales	0.00M
Book/sh	3.56
Cash/sh	3.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Apr 04, 1994

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.38
P/C	0.43
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.07
Current Ratio	15.07
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.47
EPS next Y	-1.68
EPS next Q	-0.40
EPS this Y	-15.60%
EPS next Y	-8.46%
EPS next 5Y	-5.09%
EPS past 3/5Y	86.93% 77.09%
Sales past 3/5Y	- -
EPS Y/Y TTM	-59.74%
Sales Y/Y TTM	-
EPS Q/Q	-27.69%
Sales Q/Q	-
Earnings	Jul 31 BMO
EPS/Sales Surpr.	8.21% -

Insider Own	9.30%
Insider Trans	0.00%
Inst Own	62.41%
Inst Trans	59.77%
ROA	-57.02%
ROE	-59.80%
ROIC	-57.10%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-90.31%
SMA50	-89.88%
SMA200	-88.97%
Trades

Shs Outstand	37.42M
Shs Float	33.94M
Short Float	6.03%
Short Ratio	1.70
Short Interest	2.05M
52W High	19.40 -92.96%
52W Low	5.78 -76.35%
Volatility	8.31% 8.21%
ATR (14)	1.96
RSI (14)	16.83
Beta	0.93
Rel Volume	67.49
Avg Volume	1.20M
Volume	53,576,429

Perf Week	-90.46%
Perf Month	-92.21%
Perf Quarter	-88.28%
Perf Half Y	-89.26%
Perf YTD	-88.79%
Perf Year	-76.87%
Perf 3Y	-94.31%
Perf 5Y	-99.95%
Perf 10Y	-100.00%
Recom	1.00
Target Price	32.44
Prev Close	13.44
Price	1.37
Change %	-89.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-26	Initiated	Canaccord Genuity	Buy	$35
Jul-22-26	Initiated	Evercore ISI	Outperform	$39
Jun-22-26	Initiated	Chardan Capital Markets	Buy	$27
Mar-17-26	Initiated	Cantor Fitzgerald	Overweight	$35
Sep-08-25	Initiated	Piper Sandler	Overweight	$20
Oct-24-24	Initiated	Leerink Partners	Outperform	$16
Oct-14-24	Initiated	Guggenheim	Buy	$16
Sep-30-24	Initiated	William Blair	Outperform
May-18-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-16-14	Initiated	MLV & Co	Buy	$7
Nov-18-14	Initiated	WallachBeth	Buy	$12

Show Previous Ratings

Today 11:03AM	Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 (InvestorsHub) -89.83%
10:52AM	Tenax, Sionna Shares Sink After Trial Failures (The Wall Street Journal)
10:23AM	Why Did TENX Stock Crash 89% Today? (Stocktwits)
08:25AM	Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout (Investing.com)
07:00AM	Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF (GlobeNewswire)
07:08AM	Loading…
Jul-31-26 07:08AM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press) -9.27%
07:00AM	Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-02-26 04:05PM	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.33% +5.17%
08:48AM	Three Years of War Changed What Governments Buy. One Player is Already Winning Contracts (NASDAQ: MDWD) (FinanceWire)
07:00AM	Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 (GlobeNewswire)
May-12-26 07:07AM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:00AM	Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-26 04:05PM	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-26 07:00AM	Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer (GlobeNewswire)
Apr-22-26 07:00AM	Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer (GlobeNewswire)
09:33AM	Loading…
Mar-17-26 09:33AM	DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls (The Fly) +8.51%
Mar-10-26 07:24AM	Tenax Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) +31.67%
07:00AM	Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-26 07:00AM	Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-15-26 01:03PM	Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference (MarketBeat)
Feb-04-26 07:00AM	Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 (GlobeNewswire)
Jan-08-26 02:00PM	Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick (Insider Monkey)
Dec-17-25 09:16AM	Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment (GlobeNewswire) +5.65%
Nov-25-25 07:00AM	Tenax Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-25 04:17PM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:00AM	Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF (GlobeNewswire)
Nov-03-25 07:00AM	Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Sep-16-25 07:00AM	Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF (GlobeNewswire)
Aug-28-25 07:00AM	Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 (GlobeNewswire)
04:17PM	Loading…
Aug-13-25 04:17PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-25 04:38PM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-16-25 04:29PM	Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts (Seeking Alpha)
Mar-31-25 08:00AM	Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-25 04:25PM	Tenax Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-25 08:47AM	Tenax Therapeutics Announces $25 Million Private Placement (GlobeNewswire)
08:42AM	Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF (GlobeNewswire)
Mar-03-25 08:00AM	Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference (GlobeNewswire)
Jan-31-25 09:00AM	Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:00AM	Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations (GlobeNewswire)
Nov-13-24 07:19AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-31-24 04:05PM	Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Aug-13-24 04:37PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.63%
04:05PM	Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-12-24 08:00AM	Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program (GlobeNewswire) -10.86%
Aug-06-24 07:13AM	Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement (GlobeNewswire) +28.77%
May-14-24 01:53PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:10AM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-30-24 07:30AM	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +6.27%
Apr-09-24 08:30AM	Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study (GlobeNewswire)
Mar-28-24 09:54PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +9.56% -9.91%
08:30AM	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 08:30AM	Tenax Therapeutics to Present at the 36th Annual Roth Conference (GlobeNewswire)
Feb-29-24 09:00AM	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 (GlobeNewswire) +10.87%
Feb-20-24 08:30AM	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan (GlobeNewswire)
Feb-08-24 08:53AM	Why Is Tenax Therapeutics (TENX) Stock Down 64% Today? (InvestorPlace) -64.45%
08:16AM	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering (GlobeNewswire)
Feb-07-24 08:01PM	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +24.54%
Feb-06-24 08:30AM	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +31.31%
Dec-29-23 08:30AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire) -16.79%
Nov-17-23 08:30AM	Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board (GlobeNewswire) -9.21%
Nov-14-23 05:05AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -18.55%
Nov-13-23 03:22PM	Why Is Tenax Therapeutics (TENX) Stock Up 300% Today? (InvestorPlace) +297.44%
08:30AM	Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023 (GlobeNewswire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks) -5.96%
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Jul-19-23 08:30AM	Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +10.40%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research) +9.19%
May-31-23 08:54AM	Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +13.31%
May-22-23 06:44AM	TENX: Prioritizing Levosimendan (Zacks Small Cap Research) +5.71%
Apr-21-23 03:59PM	10 Stocks Targeted By Short Sellers Recently (Insider Monkey)
Apr-12-23 02:50PM	Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure (Benzinga)
08:45AM	Tenax Therapeutics Provides 2023 Business Update (GlobeNewswire)
Apr-05-23 05:49AM	TENX: Patents Guide the Way (Zacks Small Cap Research) -7.89%
Mar-22-23 08:45AM	Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -5.36%
Feb-17-23 07:05AM	Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX) (Simply Wall St.)
Feb-15-23 08:05AM	TENX: New Funding Puts Wind in the Sails (Zacks Small Cap Research)
Feb-07-23 12:10PM	Triangle pharma raising millions amid uncertain future (American City Business Journals) -8.02%
Feb-03-23 08:19AM	Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering (GlobeNewswire) -20.81%
Feb-02-23 10:43AM	Why Tenax Therapeutics Shares Are Gaining Today? (Benzinga) +30.77%
Feb-01-23 04:31PM	Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -20.28%
Jan-04-23 08:00AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Nov-03-22 07:16AM	TENX: Agility Required to Unlock Considerable Upside (Zacks Small Cap Research) -20.03%
Oct-10-22 08:30AM	Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire)
Sep-15-22 09:29AM	Tenax Therapeutics Stock Jumps On Strategic Alternative Review (Benzinga) +11.25%
08:30AM	Tenax Therapeutics Announces the Evaluation of Strategic Alternatives (GlobeNewswire)
Aug-28-22 09:23AM	Loss-Making Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-23-22 05:58AM	TENX: The Pressures On: Awaiting Phase 3 Start (Zacks Small Cap Research)
Jul-01-22 07:52AM	Chapel Hill company given extension to regain Nasdaq compliance (American City Business Journals) +6.07%
May-25-22 08:30AM	Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) (Business Wire)
May-23-22 08:30AM	Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension (Business Wire) +6.92%
May-19-22 08:18AM	TENX: 1Q:22 Financial and Operational Review (Zacks Small Cap Research)
May-18-22 08:30AM	Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Business Wire) +7.27%
Apr-01-22 09:25AM	TENX: 2021 Financial and Operational Review (Zacks Small Cap Research)

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

CEOMr. Christopher T. Giordano

Principal Financial Officer & Principal Accounting OfficerMr. Thomas A. McGauley

Chief Medical Officer & DirectorDr. Stuart Rich M.D.

CPAMr. Thomas R. Staab II

Chief Business OfficerMr. Doug Randall

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giordano Christopher Thomas	CEO	Jul 13 '26	Option Exercise	5.88	8,719	51,267	11,324	Jul 14 07:29 PM
Rich Stuart	Chief Medical Officer	Dec 09 '25	Buy	10.22	2,500	25,542	5,266	Dec 10 06:48 PM
Rich Stuart	Chief Medical Officer	Dec 08 '25	Buy	10.10	2,500	25,250	5,000	Dec 10 06:48 PM
Rich Stuart	Chief Medical Officer	Dec 04 '25	Buy	9.20	2,500	22,998	2,500	Dec 05 05:46 PM
Rich Stuart	Chief Medical Officer	Dec 03 '25	Buy	9.08	1,500	13,618	2,766	Dec 05 05:46 PM
Rich Stuart	Chief Medical Officer	Dec 02 '25	Buy	9.01	1,000	9,006	1,266	Dec 05 05:46 PM
Giordano Christopher Thomas	CEO	Nov 18 '25	Buy	7.75	1,612	12,500	1,612	Nov 20 06:38 PM
Giordano Christopher Thomas	CEO	Nov 20 '25	Buy	7.59	538	4,083	2,605	Nov 20 06:38 PM
Giordano Christopher Thomas	CEO	Nov 19 '25	Buy	7.51	455	3,417	2,067	Nov 20 06:38 PM
MCGAULEY THOMAS	Interim CFO	Nov 17 '25	Buy	7.25	6,000	43,490	5,000	Nov 19 07:01 PM
MCGAULEY THOMAS	Interim CFO	Nov 17 '25	Buy	7.34	2,000	14,674	2,000	Nov 19 07:01 PM
Almenoff June Sherie	Director	Nov 18 '25	Buy	7.52	1,900	14,280	1,993	Nov 19 06:43 PM
Almenoff June Sherie	Director	Nov 17 '25	Buy	7.15	93	665	93	Nov 19 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TENX

Tenax Therapeutics Inc

Upgrade your Finviz experience